老年肿瘤患者的支.pptVIP

心脏毒性作用of 5HT3受体拮抗剂 have not only been associated with the concomitant use of cancer chemotherapeutic agents, but have also been observed in healthy individuals. 恩丹西酮, 32 mg i.v., has been associated with increased QTc1,2 and JT2 间期 and a decrease in heart rate2 in healthy adults compared with placebo. However, all ECG changes returned to normal within 8 小时.2 Similarly, 多拉司琼 has been associated with ECG changes.2,3 多拉司琼, 1.2, 1.8 or 2.4 mg/kg i.v., produced significant increases in heart rate and PR, QRS and QTc 间期, within the first 4 小时 post-administration.2 In contrast, 凯特瑞, 10 ?g/kg i.v., has been shown not to affect ECG parameters.1 One 研究 which examined ECG recordings following 口服 凯特瑞, 2 mg, identified some supraventricular ectopic activity and sinus bradycardia which were not sustained, and 凯特瑞 was not considered to be cardiotoxic.4 ? Boike SC, Ilson B, Zariffa N et al. Cardiovascular effects of i.v. 凯特瑞 at two administration rates and of 恩丹西酮 in healthy adults. Am J Health Syst Pharm 1997; 54: 1172–6. Benedict CR, Arbogast R, Martin L et al. Single-blind 研究 of the effects of intravenous 多拉司琼 mesylate versus 恩丹西酮 on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996; 28: 53–9. Hunt TL, Cramer M, Shah A et al. A double-blind, placebo-controlled, 剂量-ranging safety evaluation of single-剂量 intravenous 多拉司琼 in healthy male volunteers. J Clin Pharmacol 1995; 35: 705–12. Gray GW, McLellan TM, Ducharme MB. 凯特瑞 shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment. Aviat Space Environ Med 1996; 67: 759–61. The 5HT3受体拮抗剂 differ in their propensity to induce ECG changes. Adverse cardiovascular changes with these agents should therefore not be regarded as a class effect. Administration of 凯特瑞, 3 mg i.v., in cancer patients was shown to increase the mean PR间期.1 Although computer-generated ECG tracings showed this increase to be significant (p=0.02), no clinical consequences were associated with this